Sacubitril Valsartan Sodium Drugs Market - Global Forecast 2026-2032

Sacubitril valsartan sodium drugs are shaping the future of heart failure treatment as healthcare systems demand more robust, evidence-based solutions that address both clinical and operational needs. As market pressures shift and new challenges emerge, senior decision-makers are seeking objective, data-driven insights to inform strategies in this evolving landscape.

Market Snapshot: Sacubitril Valsartan Sodium Drugs Market Overview

The sacubitril valsartan sodium drugs market expanded from USD 10.58 billion in 2025 to USD 11.37 billion in 2026. With a projected CAGR of 7.75%, it is set to reach USD 17.85 billion by 2032. This strong growth reflects shifting healthcare priorities, ongoing therapy innovations, and expanding regional adoption patterns.

Scope & Segmentation

This report delivers full-spectrum analysis of the sacubitril valsartan sodium drugs market, including:

Product Strengths: Comparison across common dosage strengths, focusing on titration pathways and optimization considerations.
Dosage Forms: Emphasis on oral solid formats, stable manufacturing, and packaging aligned with pharmacy workflows.
Distribution Channels: Insights into hospital pharmacy, retail, and online pharmacy trends, including their impact on therapy initiation and persistence.
End Users: Breakdown of specialty clinics, cardiology centers, general hospitals, and broader provider networks, examining workflow influences and educational needs.
Payer Types: Evaluation of access strategies shaped by commercial insurers, public payers, and integrated delivery models.
Regions Covered: Analysis spans the Americas, Europe Middle East & Africa, and Asia-Pacific, with attention to regional adoption drivers and infrastructure readiness.

Sacubitril Valsartan Sodium Drugs: Key Takeaways

Clinical adoption now depends on more than drug efficacy, incorporating supply reliability, payer scrutiny, and real-world adherence.
Guideline-driven therapy and early intervention models are amplifying the importance of seamless titration support and efficient workflows.
Expansion into digital health is making remote monitoring and pharmacy-led adherence standard features in heart failure care strategies.
Increased supplier diversity and dual sourcing are becoming prerequisites for managing both supply continuity and operational risk exposure.
Regional success is closely linked to supply chain sophistication, payer policy adaptation, and alignment with local disease management needs.
Multi-source competition places emphasis on brand reliability, quality consistency, and post-market service differentiation.

Tariff Impact: Navigating the 2025 Supply Chain Landscape

U.S. tariffs in 2025 introduce significant complexity for sourcing sacubitril valsartan sodium drugs. Manufacturers face not only direct cost pressures but also challenges associated with global ingredient procurement and regulatory documentation for new suppliers. Short-term demand fluctuations are likely as distributors and large buyers adjust purchasing patterns in response to anticipated pricing changes. Organizations are responding by conducting scenario planning, stress-testing supply alternatives, and refining contract terms to mitigate exposure. These factors place supply resilience at the forefront of commercial planning, making proactive inventory management critical for continuity of care.

Methodology & Data Sources

This report combines rigorous secondary research—drawing from regulatory filings, policy updates, guideline publications, and peer-reviewed literature—with primary interviews across clinicians, pharmacists, payers, procurement experts, and industry leaders. Analytical triangulation and consistency checks ensure that insights reflect actual stakeholder behavior, supporting decision readiness for strategic planning and risk assessment.

Why This Report Matters

Enables precise alignment of clinical, operational, and market access strategies in the sacubitril valsartan sodium drugs segment.
Identifies key pressure points—such as tariff-driven supply risks and payer policy friction—to inform agile commercial and procurement decisions.
Helps regional and global leaders benchmark competitive positioning, from supply chain practices to technology-driven adherence initiatives.

Conclusion

In this environment, clinical evidence, payer logic, and supply certainty increasingly define sustainable strategies. Leaders best positioned for future growth are those who combine operational excellence with responsiveness to evolving regional and regulatory dynamics.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Sacubitril Valsartan Sodium Drugs Market, by Type

8.1. Brand
8.2. Generic

9. Sacubitril Valsartan Sodium Drugs Market, by Strength

9.1. 24 26 Mg
9.2. 49 51 Mg
9.3. 97 103 Mg

10. Sacubitril Valsartan Sodium Drugs Market, by End User

10.1. Clinics
10.2. Home Care
10.3. Hospitals

11. Sacubitril Valsartan Sodium Drugs Market, by Distribution Channel

11.1. Offline
11.2. Online

12. Sacubitril Valsartan Sodium Drugs Market, by Region

12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific

13. Sacubitril Valsartan Sodium Drugs Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Sacubitril Valsartan Sodium Drugs Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. United States Sacubitril Valsartan Sodium Drugs Market
16. China Sacubitril Valsartan Sodium Drugs Market

17. Competitive Landscape

17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Aspen Pharmacare Holdings Limited
17.6. Aurobindo Pharma Limited
17.7. Cipla Limited
17.8. Dr. Reddy's Laboratories Ltd.
17.9. Glenmark Pharmaceuticals Ltd.
17.10. Hetero Labs Limited
17.11. Lupin Limited
17.12. MacLeod's Pharmaceuticals Ltd.
17.13. MSN Laboratories Private Limited
17.14. Mylan N.V.
17.15. Natco Pharma Limited
17.16. Novartis AG
17.17. Orion Corporation
17.18. Pfizer Inc.
17.19. Sandoz International GmbH
17.20. Sun Pharmaceutical Industries Ltd.
17.21. Teva Pharmaceutical Industries Ltd.
17.22. Torrent Pharmaceuticals Ltd.
17.23. Zydus Lifesciences Limited

List of Figures

FIGURE 1. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BRAND, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BRAND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 24 26 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 24 26 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 24 26 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 49 51 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 49 51 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 49 51 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 97 103 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 97 103 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 97 103 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 38. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 39. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 40. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 41. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 42. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 44. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 45. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 46. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 47. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 49. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 50. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 51. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 57. EUROPE SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. EUROPE SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 59. EUROPE SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 60. EUROPE SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 61. EUROPE SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 62. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 64. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 65. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 66. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 67. AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 69. AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 70. AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 71. AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. ASEAN SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. ASEAN SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 80. ASEAN SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 81. ASEAN SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. ASEAN SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. GCC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GCC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 85. GCC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 86. GCC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. GCC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 90. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 91. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 93. BRICS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. BRICS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 95. BRICS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 96. BRICS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. BRICS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. G7 SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. G7 SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 100. G7 SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 101. G7 SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. G7 SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NATO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. NATO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 105. NATO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 106. NATO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. NATO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 110. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 111. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 112. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 115. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 116. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 117. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Sacubitril Valsartan Sodium Drugs market report include:

Aspen Pharmacare Holdings Limited
Aurobindo Pharma Limited
Cipla Limited
Dr. Reddy's Laboratories Ltd.
Glenmark Pharmaceuticals Ltd.
Hetero Labs Limited
Lupin Limited
MacLeod's Pharmaceuticals Ltd.
MSN Laboratories Private Limited
Mylan N.V.
Natco Pharma Limited
Novartis AG
Orion Corporation
Pfizer Inc.
Sandoz International GmbH
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Zydus Lifesciences Limited

Table Information

Report Attribute	Details
No. of Pages	192
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 11.37 Billion
Forecasted Market Value ( USD ) by 2032	$ 17.85 Billion
Compound Annual Growth Rate	7.7%
Regions Covered	Global
No. of Companies Mentioned	20

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3447EUR$3,939USD£2,988GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3719EUR$4,249USD£3,223GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5040EUR$5,759USD£4,368GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6099EUR$6,969USD£5,286GBP

Market Snapshot: Sacubitril Valsartan Sodium Drugs Market Overview

Scope & Segmentation

Sacubitril Valsartan Sodium Drugs: Key Takeaways

Tariff Impact: Navigating the 2025 Supply Chain Landscape

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Sacubitril Valsartan Sodium Tablets Market - Global Forecast 2026-2032

Valsartan Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Product Type

Valsartan (CAS 137862-53-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

Angiotensin Receptor Blockers (ARBs) Market Report 2025

Chronic Heart Failure Pipeline Analysis Report 2025